Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-1473 PK, Food Effect, and DDI Study
NCT03555617Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Jun 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of izencitinib in inflammatory bowel disease (IBD) (2 arms), sponsored by Theravance Biopharma, Inc. Primary endpoints: Maximum observed concentration, Time to maximum observed concentration and 5 more. Started Jun 2018; status: completed.
02
Drugs
izencitinib
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03555617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03555617.